drugset

Drugs / Donor Regulatory T-Lymphocytes

Follow last change Jun 2023 re-read 2 minutes ago

Donor Regulatory T-Lymphocytes

also known as DLI

Developed for: acute graft versus host disease · beta-thalassemia major
Investigated by: Everett Meyer · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

today NCT02526329 · Ph 1

20162017201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02526329	Aug 2015 → Nov 2022	acute graft versus host disease	Everett Meyer	Withdrawn	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT03101423 Comparator	Aug 2016 → Dec 2019	beta-thalassemia major	First Affiliated Hospital of Guangxi Medical University	Unknown	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	donor regulatory T lymphocytes	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02526329 ↗ 1 NCT03101423 ↗
Known as	DLI	“Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month” NCT03101423 ↗
Modality	Cell therapy	“Primary T Regulatory Cell Therapy” NCT02526329 ↗
Route	Intravenous	“Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0.” NCT02526329 ↗